- $1.14bn
- $897.65m
- $765.15m
- 97
- 78
- 13
- 67
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 487 | 959 | 1,306 | 886 | 765 |
Cost of Revenue | |||||
Gross Profit | 142 | 332 | 457 | 350 | 343 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 433 | 759 | 1,114 | 806 | 695 |
Operating Profit | 53.6 | 200 | 192 | 80 | 70 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 50.3 | 199 | 192 | 82 | 79.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 39.2 | 155 | 140 | 60.7 | 53.6 |
Net Income Before Extraordinary Items | |||||
Net Income | 39.2 | 155 | 140 | 60.7 | 53.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 39.2 | 155 | 140 | 60.7 | 53.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.18 | 0.699 | 0.639 | 0.285 | 0.275 |
Dividends per Share | |||||
Special Dividends per Share |